COMMUNIQUÉS West-GlobeNewswire

DiFusion to Define Therapeutic Biomaterials Category at NASS 2026
29/09/2026
Red Theater presentation will distinguish conventional biotolerable implants from materials deliberately engineered to influence the host response and participate in healing AUSTIN, Texas, Sept. 29, 2026 (GLOBE NEWSWIRE [...]
NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease
29/09/2026
- SPINOZA is studying obicetrapib in adults with biomarker evidence suggestive of preclinical Alzheimer’s disease who do not have noticeable memory or functional symptoms- - The study will evaluate changes in blood- [...]
Apyx Medical Announces New Clinical Study Demonstrating Renuvion®’s Impact on Skin Quality
29/09/2026
Patients reported high satisfaction and visible improvements in skin elasticity, youthfulness, and radiance CLEARWATER, Fla., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical” or [...]
Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD
29/09/2026
Initiation of registrational Phase 3 study of VOQUEZNA® (vonoprazan) for as-needed (PRN) use in Non-Erosive Reflux Disease (NERD) builds on previously reported positive Phase 2 data Topline results expected in the first [...]
Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron
29/09/2026
Topline Data from First-in-Human Pharmacokinetic Study Anticipated in the Fourth Quarter of 2026 TEL AVIV, Israel, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a [...]
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting
29/09/2026
NEW YORK and WALTHAM, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the [...]
Noah Medical’s Galaxy System Enters Commercial Use in Asia with First Procedure Completed in Hong Kong
29/09/2026
SAN JOSE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Medical robotics innovator Noah Medical today announced the successful completion of its first commercial procedure in Asia using the Galaxy™ System at Prince of [...]
Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda
29/09/2026
LEXINGTON, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a [...]
argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline
29/09/2026
New data show deepening improvement in ocular MG and sustained one-year efficacy in anti-AChR antibody-negative MG – broadening VYVGART's potential to treat all MG patients Real-world evidence from more than 1,100 U.S. [...]
Silexion Therapeutics Announces Exercise of Warrants
29/09/2026
Cayman Islands, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS- [...]
Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis
29/09/2026
More than 94% of participants achieved a ≥5-point MG-ADL improvement at Week 48 42% of telitacicept-treated participants achieved minimal symptom expression (MSE) at any time over 48 weeks, increasing from 23.7% over [...]
Rapid Nutrition Reports Record Q3 Group Revenue Averaging $1 Million per Month, Up More Than 1,000% on FY2025 Monthly Average
29/09/2026
Third-quarter trading marks a key milestone in the execution of the Group’s accelerated growth strategy and positions Rapid Nutrition for a record second half LONDON, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Rapid Nutrition [...]
Breye Therapeutics raises €67.5 million in over-subscribed Series A financing
29/09/2026
Co-led by new investor Mission BioCapital and existing investor Novo Holdings, with additional investment from existing syndicate member Sound Bioventures, and new investors the Ljungström family office, Innovestor Life [...]
Kither Biotech Initiates Dosing of Patients in Phase 1b / 2a Study of KIT2014 in COPD
29/09/2026
KIT2014 is a novel inhaled peptide therapy being developed for respiratory diseases including chronic obstructive pulmonary disease (COPD), non-CF bronchiectasis (NCFB), idiopathic pulmonary fibrosis (IPF) and cystic [...]
Cyprumed‘s Oral Delivery Technology Advances to Clinical Stage as MSD Initiates Phase I Trial
29/09/2026
The Phase I clinical trial will evaluate a proprietary drug candidate formulated using Cyprumed’s oral tablet technology, marking the first Cyprumed technology program to enter human clinical development The milestone [...]
Transactions in connection with share buy-back program
29/09/2026
Company announcement no. 37 - 26 29 September 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
GUERBET : Mise à disposition du Rapport Financier semestriel 2026
29/09/2026
Mise à disposition du Rapport Financier semestriel 2026 Villepinte, le 29 septembre 2026 : Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l’imagerie médicale annonce ce jour [...]
Novo and Hengrui Pharma enter exclusive license agreement for once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596
29/09/2026
HRS-1596 is a phase 1-ready GLP-1/GIP dual receptor agonist for once-weekly oral dosing Total potential deal value is up to 2.6 billion US dollars, including 300 million dollars upfront, as well as potential sales [...]
IBA signe un contrat pour installer le premier centre de protonthérapie du centre de l'Italie, à Rome
29/09/2026
Louvain-la-Neuve, Belgique, le 29 septembre 2026, 7h00 - IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’accélération de particules et principal fournisseur de solutions de protonthérapie [...]

Pages